Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione di Fuling Yunhua Granules e Dihuang Baoyuan Granules in pazienti affetti da diabete di tipo 2 naive ai farmaci

Valutazione di Fuling Yunhua Granuli e Dihuang Baoyuan Granuli in pazienti affetti da diabete di tipo 2 con scarso controllo della glicemia dopo dieta ed esercizio fisico: uno studio clinico multicentrico, randomizzato, in doppio cieco, controllato con placebo

The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention.

Panoramica dello studio

Descrizione dettagliata

This is a multicenter, randomized, double-blind, placebo-controlled study, including a up to 2-week screening period, a 1-week baseline period, a 12-week treatment period and a 1-week follow-up period.

72 participants who meet the enrollment requirements will enter the baseline period, during which 7 days of CGM data will be collected. After entering the treatment period, participants will be randomly assigned to prescription ABA group, prescription ABA-matched placebo group, prescription BAB group and prescription BAB-matched placebo group in a ratio of 2:1:2:1 and receive corresponding treatment.

It is expected that an interim analysis will be conducted after 30 participants have completed 4 weeks of treatment and 4 weeks of their data is obtained. Based on the CGM data of the participants in the 4th week of treatment, the change of TIR in the 4th week compared with the baseline will be analyzed, and the IDMC will make a decision based on the results of this analysis.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

95

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Beijing, Cina
        • Peking University People's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age 18-75 years (inclusive), male or female;
  2. Patients diagnosed with T2DM ≥ 8 weeks according to the 2020 WHO diagnostic criteria and classification;
  3. Have controlled blood sugar through diet and exercise for 3 months before screening and did not receive any hypoglycemic drugs, or used hypoglycemic drugs for no more than 2 weeks within 3 months before screening and did not use hypoglycemic drugs within 1 month before screening;
  4. Body mass index (BMI) ≥ 19 kg/m2;
  5. Glycated hemoglobin (HbA1c) ≥ 7.0% and < 10.5% at screening;
  6. Fasting plasma glucose (FPG) < 13.9 mmol/L at screening;
  7. Able to understand the procedures and methods of this study, willing to strictly abide by the clinical research protocol to complete this study, and voluntarily sign the ICF

Exclusion Criteria:

  1. Non-type 2 diabetes: type 1 diabetes, gestational diabetes, special types of diabetes;

  2. History of acute complications of diabetes within 6 months before screening (diabetic ketoacidosis, diabetic hyperglycemic hyperosmolar syndrome or lactic acidosis, etc.);

  3. History of chronic complications of diabetes with unstable condition or requiring treatment within 6 months before screening (proliferative retinal disease, severe diabetic neuropathy or intermittent claudication, etc.);

  4. Experienced more than 3 episodes of grade 3 hypoglycemia within 6 months before screening;

  5. Have used systemic (intravenous, oral or intra-articular) glucocorticoids continuously or cumulatively for ≥ 7 days within 3 months before screening;

  6. Severe infection within 3 months before screening;

  7. Diagnosed with malignant tumors within 5 years before screening (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix);

  8. Severe cardiovascular disease, such as heart failure (New York Heart Association [NYHA] grade III-IV), myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention, occurred within 6 months before screening, Sustained and clinically significant arrhythmia (such as second- or third-degree atrioventricular block or QTc interval prolongation ≥470 ms in men and ≥480 ms in women), acute coronary syndrome or transient ischemic attack or stroke wait;

  9. Suffering from diseases that may significantly affect drug absorption, distribution, metabolism and excretion within 6 months before screening: inflammatory bowel disease, peptic ulcer, history of gastrointestinal or rectal bleeding, history of important gastrointestinal surgery (such as : Gastrectomy, gastrointestinal anastomosis, or intestinal resection), etc.;

  10. Accompanied by thyroid dysfunction that cannot be controlled with stable drug dosage during screening;

  11. History of hypertension and take antihypertensive treatment regularly for more than 4 weeks but still have poor blood pressure control, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg;

  12. History of organ transplantation or severe autoimmune diseases in the past or present;

  13. History of clinically significant drug allergy or atopic allergic disease (asthma, urticaria, eczematous dermatitis);

  14. History of major surgery (intrathoracic, intracranial, abdominal, etc.) within 6 months before screening, or those who plan to undergo surgery during the study that may affect study completion or compliance;

  15. Any laboratory test meets any of the following criteria during screening:

    Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN) × 2.5 times Glomerular filtration rate (eGFR) calculated using the CKD-EPI formula < 60 mL/min /1.73m2 Total bilirubin (TBIL)>ULN×1.5 times Fasting triglyceride (TG)>5.7 mmol/L Fasting C-peptide <0.8 ng/ml (or 0.26 nmol/L)

  16. Those who are positive for hepatitis B surface antigen during screening (except those whose quantitative test results of hepatitis B virus deoxyribonucleic acid [HBV-DNA] are lower than the lower limit of the detection reference range and who are not using anti-hepatitis B virus drugs during screening), or who are receiving anti-hepatitis B virus drug treatment , or those who are hepatitis C virus (HCV) antibody positive, or human immunodeficiency virus (HIV) antibody positive, or Treponema pallidum antibody positive;

  17. Blood donation or massive blood loss (>400 mL) within 3 months before screening;

  18. Pregnant or lactating women, or men or women of childbearing potential who plan to become pregnant during the study or are unwilling to take medically recognized contraceptive measures;

  19. History of alcohol, tobacco addiction or drug abuse is known or suspected at the time of screening;

  20. Participated in any interventional drug clinical research within 3 months before screening;

  21. Allergic to study drugs and their ingredients;

  22. Participants who the researcher believes have any other factors that are inappropriate for participating in this study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: prescription ABA

Fuling Yunhua Granules and Dihuang Baoyuan Granules

Fuling Yunhua Granules

Altri nomi:
  • prescrizione A
Sperimentale: prescription BAB

Fuling Yunhua Granules and Dihuang Baoyuan Granules

Dihuang Baoyuan Granules

Altri nomi:
  • prescrizione B
Comparatore placebo: prescription ABA-matched placebo/ BAB-matched placebo

Fuling Yunhua Granules placebo and Dihuang Baoyuan Granules placebo

Fuling Yunhua Granules placebo/Dihuang Baoyuan Granules placebo

Altri nomi:
  • prescription A matched placebo/B matched placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in HbA1c Concentrations (%) From Baseline
Lasso di tempo: 12 weeks

Change in HbA1c concentrations (%) from baseline is the numerical difference between a participant's hemoglobin A1c (HbA1c) level at a specified follow-up time point(s) and their baseline level (initial assessment before intervention). HbA1c, a glycated hemoglobin biomarker, reflects average blood glucose over 8-12 weeks. Venous blood is collected via standard phlebotomy, and HbA1c is quantified using a laboratory-certified method (e.g., high-performance liquid chromatography [HPLC] or immunoassay) for accuracy. Calculated as: Follow-up HbA1c (%) - Baseline HbA1c (%), positive values mean increased average blood glucose, negative values mean decreased. This metric evaluates intervention efficacy (e.g., medications, lifestyle modifications) for glycemic control in diabetes or prediabetes populations.

12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in FPG (mmol/L) From Baseline
Lasso di tempo: 12 weeks

Change in Fasting Plasma Glucose (FPG) (mmol/L) from baseline is the numerical difference between a participant's FPG level at follow-up and their baseline FPG. FPG measures plasma glucose concentration after an 8-12 hour fast, reflecting overnight glycemic control. Venous blood samples are collected via standard phlebotomy, with glucose quantified using laboratory methods (e.g., hexokinase assay). Calculated as: Follow-up FPG (mmol/L) - Baseline FPG (mmol/L), positive values indicate increased fasting glucose, negative values a decrease. This metric assesses intervention efficacy in regulating fasting glycemia, critical for diabetes management.

12 weeks
The Proportion of Participants Who Achieved HbA1c Target
Lasso di tempo: 12 weeks

The proportion of participants who achieved HbA1c target (HbA1c<7.0% and <6.5% Patient percentage)

12 weeks
Changes in TIR From Baseline
Lasso di tempo: 12 weeks

Changes in Time in Range (TIR) from baseline refers to the difference between a participant's TIR at follow-up and their baseline TIR. TIR is the percentage of time blood glucose levels stay within a target range (typically 3.9-10.0 mmol/L [70-180 mg/dL] for most people with diabetes) over a specified period, measured via continuous glucose monitoring (CGM) devices. Calculated as: Follow-up TIR (%) - Baseline TIR (%), positive values indicate increased time in target range, negative values a decrease. This metric assesses glycemic stability and intervention effectiveness (e.g., medication adjustments, lifestyle changes) in managing blood glucose control.

12 weeks
Changes in TBR From Baseline
Lasso di tempo: 12 weeks

Changes in Time Below Range (TBR) from baseline is the difference between a participant's TBR at follow-up and their baseline TBR. TBR is the percentage of time blood glucose levels fall below a target range (e.g., <3.9 mmol/L [70 mg/dL] for adults) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TBR (%) - Baseline TBR (%), positive values indicate increased time below range, negative values a decrease. This metric evaluates risks of hypoglycemia and intervention impact on maintaining glucose above target levels.

12 weeks
Changes in TAR From Baseline
Lasso di tempo: 12 weeks

Changes in Time Above Range (TAR) from baseline refers to the difference between a participant's TAR at follow-up and their baseline TAR. TAR is the percentage of time blood glucose levels exceed a target range (e.g., >10.0 mmol/L [180 mg/dL] for most adults with diabetes) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TAR (%) - Baseline TAR (%), positive values indicate increased time above range, negative values a decrease. This metric assesses risks of hyperglycemia and intervention effectiveness in keeping glucose within target levels.

12 weeks
Changes in MAGE From Baseline
Lasso di tempo: 12 weeks

Changes in Mean Amplitude of Glycemic Excursions (MAGE) from baseline is the difference between a participant's MAGE at follow-up and their baseline MAGE. MAGE quantifies the average magnitude of significant blood glucose fluctuations (exceeding a threshold, typically 1.4 mmol/L [25 mg/dL]) over a specified period, derived from continuous glucose monitoring (CGM) data. Calculated as: Follow-up MAGE - Baseline MAGE, higher values indicate greater glycemic variability, lower values more stable glucose. This metric evaluates intervention impact on reducing glucose swings, relevant for assessing glycemic stability in diabetes management.

12 weeks
Change From Baseline in Total Cholesterol (TC) at Week 12
Lasso di tempo: 12 weeks

TTotal cholesterol (TC) was measured in venous blood samples and reported in mmol/L. Change from baseline was calculated as the TC value at Week 12 minus the baseline TC value. Negative values indicate a reduction in total cholesterol.

12 weeks
Change From Baseline in Body Weight at Week 12
Lasso di tempo: 12 weeks

Body weight was measured in kilograms. Change from baseline was calculated as body weight at Week 12 minus baseline body weight. Negative values indicate weight loss, and positive values indicate weight gain.

12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

31 luglio 2024

Completamento primario (Effettivo)

27 gennaio 2025

Completamento dello studio (Effettivo)

27 gennaio 2025

Date di iscrizione allo studio

Primo inviato

19 agosto 2024

Primo inviato che soddisfa i criteri di controllo qualità

26 agosto 2024

Primo Inserito (Effettivo)

28 agosto 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • JYHS-BAIIT-Pro-24001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

There is no plan to make individual participant data (IPD) available to other researchers.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi